Xbiotech announces first patient enrolled into the french national cancer institute (inca) sponsored phase i/ii/iii clinical study for natrunix™ therapy for colorectal cancer

Inca funded phase i/ii/iii study for natrunix in combination with trifluridine/tipiracil, the taskin study, launches at 20 leading medical centers in france inca funded phase i/ii/iii study for natrunix in combination with trifluridine/tipiracil, the taskin study, launches at 20 leading medical centers in france
XBIT Ratings Summary
XBIT Quant Ranking